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Dear Editor,
Atypical hemolytic–uremic syndrome (aHUS) is an extremely
rare, genetic, chronic, and progressive inﬂammatory disease1
caused by defects in complement system. These defects result
in systemic thrombotic microangiopathy involving damage
to multiple organ systems including renal dysfunction.1–7
Genetic mutations have been detected in around 50% of the
reported cases. Regarding renal transplant patients, expanded
criteria donors, infection by cytomegalovirus or BK, use of CNI
or m-TOR  inhibitors and antibody-mediated rejection (AMR)
have been related to de novo post-transplant aHUS.8 Graft
failure is reported in 60–90% of patients within 1 year.10 Eculi-
zumab is a monoclonal antibody that binds to C5 complement
protein avoiding the formation of the cell membrane attack
complex.6,7 We  report herein a case of late onset of de novo
post-transplant aHUS on a simultaneous pancreas and kidney
recipient with severe systemic manifestations, without pre-
senting acute graft rejection, successfully treated with limited
doses of eculizumab remaining stable after one year of follow-
up.
A 46-year-old woman with end stage renal disease secon-
dary to type 1 Diabetes Mellitus underwent simultaneous
pancreas and kidney transplant on October 2012 from
deceased donor. Received induction with Basiliximab and
maintenance treatment with mycophenolate mofetil, tacro-
limus, and prednisone. Pancreatic and renal function were
stable, creatinine (SCr) of 110 mol/L. Tacrolimus through
levels remained between 6 and 8 ng/ml. Seven months after
transplant presented fever, abdominal pain, diarrhea and
vomiting, acute graft dysfunction (SCr 438 mol/L) and throm-
bocytopenia (53 × 10 × 9/L). She developed progressive anemiancreas  and  kidney
 treated  with  eculizumab
olítico–urémico  atípico  de  novo
ático  resuelto  con  eculizumab
and thrombocytopenia and worsening of renal function requi-
ring dialysis. Pancreas graft function remained preserved.
Thrombotyc microangiopathy (TMA)was detected with lactate
dehydrogenase (LDH) up to 1500 UI/L, undetectable hapto-
globin and schistocytes. C3 was low, ADAMTS 13 of 79%
and Shigella toxin was negative. Urinary tract infection by
extended-spectrum beta-lactamase (ESBL)-klebsiella was pre-
sent. Initial biopsy conﬁrmed ﬁndings of TMA  with severe
tubulo-interstitial involvement and some focal glomerular
involvement, without features of acute rejection. Disconti-
nuation of tacrolimus, antibiotic treatment with meropenem
and daily plasma exchange (PE) for 10 days were performed.
The patient did not respond to therapy. Second renal biopsy
showed persistent signs of TMA, worsening involvement of
glomeruli with mesangiolysis without rejection (Fig. 1). Treat-
ment with Eculizumab was started with 4 doses of 900 mg
Eculizumab iv on a weekly basis, showing improvement of
renal function, cessation of hemodialysis and hemolysis.
Genetic screening did not detect mutations on factor I, factor
H or factor MCP genes. Risk haplotype in heterozygosis for fac-
tor H and MCP genes were observed. Study of the complement
alternate pathway showed low factor C3, factor H, normal
expression of MCP  (membrane cofactor protein) and nega-
tive anti-factor H antibodies. A third biopsy was performed
showing predominance of chronic lessions of TMA  and mild
signs of acute TMA with interstitial ﬁbrosis of 5–10% and some
microhemorrhages, with ATN (Fig. 2). New course of 3 daily PE
and ﬁnal dose of 1200 mg  of Eculizumab iv were prescribed.
She presented normalized C3, LDH, haptoglobin, hemoglobin
and platelets. At discharge Scr was 300 mol/L. Immunosupre-
sive maintenance therapy at discharge was prednisone and
mycophenolate mofetil. Renal function continued to improve
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Fig. 1 – Acute TMA  showing thrombosis at glomerular
capillaries and mesangiolysis (Masson’s trichrome stain).
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provided sustained improvement. Further evidence is needed
to establish the optimal dosing in different clinical settings.
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